English
aclarubicin
Sign in to saveAlso known as Aclacinomycin A
Aclarubicin (INN) or aclacinomycin A is an anthracycline drug that is used in the treatment of cancer in China. It was previously approved for use in Europe but was discontinued in 2004 due to being rarely prescribed and unprofitable.
Research
1,054 papers- Aclarubicin: contemporary insights into its mechanism of action, toxicity, pharmacokinetics, and clinical standing.Cancer chemotherapy and pharmacology · 2024
- Potent immune-dependent anticancer effects of the non-cardiotoxic anthracycline aclarubicin.Oncoimmunology · 2025
- Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ.International journal of molecular sciences · 2024
- Aclarubicin: preclinical and clinical data suggesting less chronic cardiotoxicity compared with conventional anthracyclines.European journal of haematology. Supplementum · 1987
- Aclarubicin stimulates RNA polymerase II elongation at closely spaced divergent promoters.Science advances · 2023
via PubMed
~1 min read
Encyclopedic overview
1 sectionsContents
- References
Aclarubicin (INN) or aclacinomycin A is an anthracycline drug that is used in the treatment of cancer in China. It was previously approved for use in Europe but was discontinued in 2004 due to being rarely prescribed and unprofitable.
However, it has subsequently been reevaluated due to possible advantages over other chemotherapeutic drugs in the treatment of certain cancers such as acute myeloid leukemia.
Excerpted from Wikipedia’s “aclarubicin” article, available under the CC BY-SA 4.0 licence.